Phase 1 study of ACE910 in healthy volunteers and hemophilia A patients

Trial Profile

Phase 1 study of ACE910 in healthy volunteers and hemophilia A patients

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 26 May 2016 Results (n=18) published in the New England Journal of Medicine
    • 26 May 2016 Results of 18 patients with haemophilia A were published in a Chugai Pharmaceutical media release.
    • 01 Dec 2015 Results (n=62) from the dose escalation part in healthy male volunteers published in the Blood.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top